Content deleted Content added
m remove square brackets from bare URL inline refs. The URL is much more helpful than a random number |
|||
Line 11:
}}
'''Advanced Accelerator Applications''' ('''AAA''' or '''Adacap''') is a [[pharmaceutical]] group specialized in the field of [[nuclear medicine]].<ref name="AAA1">[http://www.privateequitywire.co.uk/2014/02/18/197348/advanced-accelerator-applications-completes-eur41m-fundraising PrivateEquityWire, "Advanced Accelerator Applications completes fundraising", Feb 18th, 2014]</ref>
The group operates in all three segments of nuclear medicine ([[Positron emission tomography|PET]], [[SPECT]] and therapy) to diagnose and treat serious conditions in the fields of [[oncology]], [[neurology]], [[cardiology]], infectious and inflammatory [[diseases]].<ref name="AAA2">[http://www.ilsole24ore.com/art/impresa-e-territori/2014-03-12/dal-cern-biopark-canavese-064227.shtml?uuid=ABvohR2&fromSearch Il Sole 24 Ore,
In late October 2017, ''[[Reuters]]'' announced that [[Novartis]] would acquire the company for $3.9 billion, paying $41 per ordinary share and $82 per American depositary share representing a 47 percent premium.<ref>{{Cite news|url=http://uk.reuters.com/article/uk-novartis-advanced-accelerator/novartis-to-buy-frances-advanced-accelerator-for-3-9-billion-idUKKBN1CZ0KM|title = Novartis to buy French cancer specialist AAA for $3.9 billion|newspaper = Reuters|date = 3 November 2017|last1 = Miller|first1 = John}}</ref> On January 22, 2018, Novartis AG (NYSE: NVS) announced the successful completion of the tender offer by its subsidiary, Novartis Groupe France S.A.<ref>[https://www.dddmag.com/news/2018/01/novartis-completes-tender-offer-advanced-accelerator-applications''Novartis Completes Tender Offer for Advanced Accelerator Applications Jan 2018]</ref>
Line 17:
==History==
AAA was created in 2002 by Italian physicist [[Stefano Buono]] to exploit a patent from the European Organization for Nuclear Research ([[CERN]]).<ref name="AAA5">[http://www.adnkronos.com/Archivio/AdnAgenzia/2010/03/19/Economia/Ricerca-da-Rubbia-a-AAA-fisico-italiano-sfonda-con-impresa-europeaAdnkronos_135335.php AdnKronos,
AAA currently has a total of 31 sites in 12 countries, including: 19 production facilities in 8 countries (in Europe and the U.S.) that manufacture targeted radioligand therapies and precision imaging radioligands, and 6 sites with R&D activity.
Line 192:
AAA has a broad pipeline of products in development, including several theragnostic pairings for oncology indications.
NETSPOT and SomaKit TOC are novel kits for radiolabeling somatostatin analogue peptides to help diagnose somatostatin receptor-positive NET lesions. Each kit has received orphan drug designation from both the EMA and the FDA.<ref name="AAA17">[http://www.devicespace.com/News/advanced-accelerator-applications-receives-orphan/325871 Devicespace.com,
99MTc-rhAnnexin V-128, a [[SPECT]] investigational candidate for the diagnosis and assessment of apoptotic and necrotic processes, which are present in a number of pathological conditions in oncology and cardiovascular disease, as well as in autoimmune disorders. 99MTc-rhAnnexin V-128 is currently in a Phase I/II trial for the diagnosis of rheumatoid arthritis and ankylosing spondylitis, as well as several Phase II studies in cardiovascular, cardio-oncology, and pulmonary indications.
Line 207:
==Millburn site==
In 2016, AAA opened a light manufacturing and distribution site in Millburn, NJ, a residential town in North Jersey.<ref name="AAA24">Danielle Desisto. [http://archive.northjersey.com/news/drug-manufacturer-that-raised-ire-opens-1.1638411 "Millburn manufacturing site safely produces cancer-fighting drug"].</ref> When the site was first purchased, it caused substantial concerns among local residents.<ref name="AAA19">[http://archive.northjersey.com/news/business/radioactive-medicine-site-causes-concerns-1.1327213 "Concerns raised about proposed cancer drug factory in Millburn"]</ref> Per the requests of Millburn Residents, the Township Committee hired a nuclear/radiology expert to re-assess the appropriateness of opening a radioactive manufacturing site in the residential area.<ref name="AAA20">Cecilia Levine. [http://theitem.northjersey.com/epaper/viewer.aspx "Nuclear meds expert hired"]. ''The Record''. 7 May 2015.</ref> The expert concluded that the proposed operations at AAA are safe and pose no hazard to the citizens of Millburn.<ref name="AAA22">Jonathan Sym. [https://www.tapinto.net/towns/millburn-slash-short-hills/categories/millburn-slash-short-hills-top-stories/articles/advanced-accelerator-application-investigation-re "Advanced Accelerator Application Investigation Results: Risks Are
==References==
| |||